Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Articles|November 16, 2026

FDA Approves AstraZeneca's Gefurulimab (Klygefa) for Generalized MG

Listen
0:00 / 0:00

Key Takeaways

  • FDA cleared gefurulimab (Klygefa) for adults with AChR antibody–positive gMG as a once-weekly subcutaneous, self-administered dual-binding nanobody C5 inhibitor.
  • PREVAIL randomized 260 patients across 20 countries to gefurulimab vs placebo for 26 weeks with weight-based loading and weekly maintenance dosing starting day 8.
SHOW MORE

Once-weekly self-injected gefurulimab improved daily-living scores in AChR-positive generalized myasthenia gravis in the 260-patient PREVAIL trial.

FDA has approved gefurulimab (Klygefa), developed by Alexion, AstraZeneca Rare Disease, for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, AstraZeneca announced on November 16, 2026.¹ Gefurulimab is a dual-binding nanobody complement C5 inhibitor that patients inject themselves under the skin once a week with an autoinjector. The approval was based on the pivotal phase 3 PREVAIL trial.¹

Key facts

  • Drug: gefurulimab (Klygefa; Alexion, AstraZeneca Rare Disease)
  • Class: Dual-binding nanobody complement C5 inhibitor (also binds albumin)
  • Indication: Adults with AChR antibody-positive generalized myasthenia gravis
  • Administration: Once-weekly subcutaneous self-injection via autoinjector
  • Trial: PREVAIL (NCT05556096); phase 3, randomized, placebo-controlled, n=260
  • Primary end point met: MG-ADL difference -1.6 vs placebo at week 26 (p<.0001)
  • Onset: Clinical improvement as early as week 1
  • Safety: Most common TEAEs were injection site reactions, back pain, and vomiting
  • Approval: FDA (US), announced November 16, 2026
  • Other approvals: EU, Japan, and other countries; China under review

“With this approval, patients in the US gain a targeted treatment option that empowers greater autonomy with the established efficacy of C5 complement inhibition,” said Kelly Gwathmey, MD, associate professor of neurology at Columbia University Vagelos College of Physicians and Surgeons and a principal investigator in the trial at Virginia Commonwealth University, in a company press release.¹

What did the PREVAIL trial show?

PREVAIL (NCT05556096) enrolled 260 adults with AChR antibody-positive gMG from 20 countries, randomized 1:1 to gefurulimab or placebo for 26 weeks.¹,² Patients received a weight-based loading dose on day 1, followed by weekly weight-based maintenance doses starting on day 8.¹

Gefurulimab met the primary end point, improving the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score from baseline at week 26 vs placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p<.0001). Clinical improvement was seen as early as week 1.¹

In the published trial results, the Quantitative Myasthenia Gravis (QMG) score improved by 4.5 points with gefurulimab vs 2.4 points with placebo (difference: -2.1 [95% CI: -3.1, -1.1], p<.001). An MG-ADL reduction of at least 3 points was reached by 65.6% of patients on gefurulimab vs 52.1% on placebo.³ Rescue therapy was used by 5.3% of gefurulimab-treated patients and 12.4% of placebo-treated patients.³

What was the safety profile?

Gefurulimab was generally well tolerated, and its safety profile was consistent with previous gMG trials of the C5 inhibitors eculizumab and ravulizumab.¹ Rates of treatment-emergent adverse events (TEAEs) were similar between the gefurulimab and placebo groups, and most were grade 1 or 2.¹ The most common TEAEs with gefurulimab were injection site reactions (12%), back pain (8%), and vomiting (5%).¹

How does gefurulimab work?

Gefurulimab binds the C5 protein in the terminal complement cascade. When that cascade is activated in an uncontrolled way, the immune system attacks healthy cells.¹ In AChR antibody-positive gMG, antibodies that bind receptors at the neuromuscular junction activate complement, causing inflammation and disrupting communication between nerves and muscles.¹ The nanobody also binds serum albumin, which extends its half-life and allows once-weekly dosing.¹

Why does a self-administered C5 inhibitor matter?

An estimated 98,500 people in the United States are diagnosed with gMG, including 81,000 who are AChR antibody positive.¹ Gefurulimab offers C5 inhibition as a once-weekly injection that patients can give themselves. “Because no two patients experience gMG in the same way, expanding the range of options available is fundamental to how we improve lives,” said Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America.¹ Gefurulimab is also approved in the European Unioin, Japan, and other countries, and applications are under review in China and additional countries.¹

What are the limitations?

The placebo-controlled period lasted 26 weeks, and long-term efficacy and safety are being evaluated in an ongoing open-label extension.¹,² PREVAIL compared gefurulimab with placebo, not with intravenous C5 inhibitors or other gMG therapies, so how it compares with them is unknown. The approval applies only to adults with AChR antibody-positive gMG. The release does not give the FDA approval date or describe label warnings or risk management requirements.

References

  1. AstraZeneca. Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients. Press release. Published November 16, 2026. Accessed November 16, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/klygefa-gefurulimab-approved-in-the-US.html
  2. Safety and efficacy of ALXN1720 in adults with generalized myasthenia gravis. ClinicalTrials.gov; NCT05556096. Updated June 17, 2026. Accessed November 16, 2026. https://clinicaltrials.gov/study/NCT05556096
  3. Gwathmey KG, Saccà F, Howard JF Jr, et al. Efficacy and safety of gefurulimab in generalized myasthenia gravis: the PREVAIL phase 3 randomized clinical trial. JAMA Neurol. 2026;83(9):841-850. doi:10.1001/jamaneurol.2026.2333

Related to this article